Article Text

PDF

Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis.
  1. P Peichl,
  2. M Ceska,
  3. H Broell,
  4. F Effenberger,
  5. I J Lindley
  1. Sandoz Forschungsinstitut, Vienna, Austria.

    Abstract

    Human neutrophil activating peptide/interleukin 8 (NAP-1/IL-8) has been shown to activate neutrophils to degranulate in vitro and to be a potent chemotactic agonist for neutrophils and lymphocytes in vitro and in vivo. It may therefore be a mediator of inflammatory conditions such as rheumatoid arthritis (RA). Levels of NAP-1/IL-8 were low or undetectable in serum samples from 53 patients with RA. Circulating levels of antibodies to NAP-1/IL-8 showed a strong correlation with the level of quantified C reactive protein and with the number of arthritic joints. These autoantibodies, in a similar manner to quantified C reactive protein, correlated with disease activity and are associated with a lack of clinical improvement when the patient is treated with systemic steroids. This observation indicates an important role for interleukin 8 and its autoantibodies in the inflammatory processes of RA, and may provide a clinically useful marker for the diagnosis of disease severity.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.